Galapagos and GlaxoSmithKline expand anti-infectives alliance
Galapagos NV announced that it has expanded the alliance in antibacterials and antivirals with GlaxoSmithKline (GSK) to include three more discovery targets. For this expansion, Galapagos receives a payment from GSK of €2 million cash.
In December 2007, GSK and Galapagos initiated a program to discover and develop novel anti-infective drug candidates for GSK's Infectious Diseases Centre of Excellence in Drug Discovery (ID CEDD). Galapagos is responsible for the discovery and development of natural product drug candidates through to clinical Proof of Concept, at which point GSK will have exclusive option to license each compound for further development and commercialization on a worldwide basis. The new agreement further broadens the scope of the alliance between the two companies through the nomination of three additional GSK targets.
Under the terms of the alliance, Galapagos could be eligible to receive up to €95 million in upfront fees, development and regulatory milestones payments for each product candidate. If a product is commercialized, Galapagos may receive up to €120 million for achievement of specific sales milestones. Galapagos is also eligible to receive up to double-digit royalties on worldwide sales of alliance products.
Other news from the department business & finance
